At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Zometadrug
Likely dose
Zometa 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Phase 2 Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Advanced Malignant Mesothelioma
In Brief
A Phase 2 clinical trial evaluating Zometa for Mesothelioma. Completed, enrolled 8 participants across 1 site.
Detailed Summary
The primary objective of this trial is to determine the response rate of single agent zoledronic acid using a composite of criteria including the EORTC modified RECIST criteria and the EORTC tumor response criteria for 18F-FDG PET scans.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMesothelioma
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedSep 2010
Primary CompletionApr 2015
Study CompletionApr 2016
TodayJul 2026
First PostedSep 17, 2010
Enrollment StartJun 1, 2009
Primary CompletionApr 1, 2015
Study CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 15.8 years ago
Interventions
Zometadrug
Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.